Drugs that contain Belumosudil Mesylate
1. Drug name - REZUROCK
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8357693 | KADMON PHARMS LLC | Pharmacokinetically improved compounds |
Oct, 2029
(7 years from now) | |
| CN101208094A | KADMON PHARMS LLC | Pharmacokinetic Improved Compounds |
Mar, 2026
(3 years from now) | |
| CN101208094B | KADMON PHARMS LLC | Improved Pharmacokinetics Of Compound |
Mar, 2026
(3 years from now) | |
| IN200707965P1 | KADMON PHARMS LLC | Pharmacokinetically Improved Compounds |
Mar, 2026
(3 years from now) | |
| IN291914B | KADMON PHARMS LLC | Pharmacokinetically Improved Compounds |
Mar, 2026
(3 years from now) | |
| EP1865958A4 | KADMON PHARMS LLC | Pharmacokinetically Improved Compounds |
Mar, 2026
(3 years from now) | |
| EP1865958B1 | KADMON PHARMS LLC | Pharmacokinetically Improved Compounds |
Mar, 2026
(3 years from now) | |
| EP1865958A2 | KADMON PHARMS LLC | Pharmacokinetically Improved Compounds |
Mar, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10696660 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(11 years from now) | |
| US10183931 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(11 years from now) | |
| US9815820 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(11 years from now) | |
Treatment: For the treatment of chronic graft versus host disease; For the treatment of chronic graft versus hold disease
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 200MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.